

- Interleukin (IL)-23 and IL-17 play an important role in the development of psoriasis.
- Many of the new biologic drugs targeting IL-23 and IL-17 have been shown to be both safe and effective in treating moderate-to-severe plaque psoriasis. Long-term safety data still need to be established.
- These drugs are more selective with inhibition of “downstream” targets in the immunopathogenesis of psoriasis.

This summary slide represents the opinions of the authors. No funding or sponsorship was received for publication of this article. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).